Regeneron Announces COVID-19 Trial to Begin
As the news keeps coming in fast and furious on the coronavirus pandemic, most of it upsetting, there is some positive news to report. BCW Member Regeneron today announced that it has already begun trials for a COVID-19 treatment. While it won’t happen overnight, it is comforting to know that a leader right here in Westchester and a member of the BCW is taking steps to combat the virus.
Regeneron announced that it has launched a clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19 infection. This U.S.-based trial will begin at medical centers in New York, and will assess the safety of adding Kevzara to usual supportive care. Kevzara, a fully-human monoclonal antibody, may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19.
The multi-center, double-blind, Phase 2/3 trial has two parts and is anticipated to enroll up to 400 patients. The first part will recruit patients with severe COVID-19 infection across approximately 16 U.S. sites, and will evaluate the impact of Kevzara on fever and patients’ need for supplemental oxygen. The second, larger part of the trial, will evaluate the improvement in longer-term outcomes including preventing death and reducing the need for mechanical ventilation, supplemental oxygen and/or hospitalization.
While it is difficult for most of us who do not specialize in this area to understand just how Kevzara® works, it is providing a ray of hope for those afflicted and their families. And those in the industry are marveling at the speed in which this is happening. George D. Yancopoulos, M.D., Ph.D., Co-founder, President and Chief Scientific Officer of Regeneron, explained how the trials will work.
“To initiate this trial quickly, so that the results may inform evidence-based treatment of this ongoing pandemic, Regeneron and Sanofi have worked closely with the U.S. Food and Drug Administration and the Biomedical Advanced Research and Development Authority, also known as the FDA and BARDA,” he said. “Data from China suggest that the IL-6 pathway may play an important role in the overactive inflammatory response in the lungs of patients with COVID-19. Despite this encouraging finding, it’s imperative to conduct a properly designed, randomized trial to understand the true impact. Our trial is the first controlled trial in the U.S. to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients. In addition to our Kevzara program, Regeneron is also rapidly advancing a novel antibody cocktail for the prevention and treatment of COVID-19, which we hope to have available for human testing this summer.”
We thank Regeneron and the clinical team working on these developments for giving us hope. We pray that the work of scientists like those at Regeneron will help us to put this dark chapter behind us. READ MORE ABOUT THE TRIAL.
Similar News Items
The Business Council of Westchester released its 2024 Legislative Agenda and called on state lawmakers to embrace policies that support a sustainable economy and job creation. The BCW produces the Annual Legislative Agenda each year for federal, state and local representatives on behalf of the business community. Among the recommendations in its 44-page report, the […]
The Business Council of Westchester is among 43 business organizations representing tens of thousands of businesses of all sectors and sizes across New York urging the Senate and Assembly to allocate funding in the Fiscal Year 2025 budget to address the unemployment insurance debt; as well as support the Governor’s proposals to sunset the state’s […]
Congratulations to the Burn Center at Westchester Medical Center on being verified by the American Burn Association (ABA) as an Adult and Pediatric Burn Center. The verification was made after a rigorous and thorough review of Westchester Medical Center’s burn care program. With this verification, BCW Member Westchester Medical Center is now home to the […]
Become A Member
Join the county’s largest and most influential business organization today.JOIN NOW!